These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31239086)

  • 21. Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series.
    DeVido J; Connery H; Hill KP
    J Opioid Manag; 2015; 11(4):363-6. PubMed ID: 26312963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naloxone nasal spray.
    Drug Ther Bull; 2019 Sep; 57(9):137-140. PubMed ID: 31296655
    [No Abstract]   [Full Text] [Related]  

  • 23. Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program.
    Katzman JG; Takeda MY; Greenberg N; Moya Balasch M; Alchbli A; Katzman WG; Salvador JG; Bhatt SR
    JAMA Netw Open; 2020 Feb; 3(2):e200117. PubMed ID: 32101312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naloxone (Narcan) nasal spray for opioid overdose.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):1-2. PubMed ID: 26714239
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: Is nebulised naloxone effective in opioid overdose?
    Ishiyama D; Jones J
    Emerg Med J; 2013 Oct; 30(10):860. PubMed ID: 24014692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Easy-to-use overdose antidote earns fast-track approval.
    Kuehn BM
    JAMA; 2014 Apr 23-30; 311(16):1600. PubMed ID: 24756492
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacist-led health-system approaches to reduce opioid overdose and death.
    Saldaña SN; Weaver N; Stanford B
    J Am Pharm Assoc (2003); 2017; 57(2S):S8-S9. PubMed ID: 27865761
    [No Abstract]   [Full Text] [Related]  

  • 29. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.
    Debelak K; Morrone WR; O'Grady KE; Jones HE
    Am J Addict; 2013; 22(3):252-4. PubMed ID: 23617867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caring for patients with opioid use disorder in the hospital.
    Donroe JH; Holt SR; Tetrault JM
    CMAJ; 2016 Dec; 188(17-18):1232-1239. PubMed ID: 27647616
    [No Abstract]   [Full Text] [Related]  

  • 31. Bringing naloxone to ground zero: Huntington, West Virginia.
    Babcock C; Rockich-Winston N; Booth C
    J Am Pharm Assoc (2003); 2017; 57(2S):S9-S10. PubMed ID: 27838389
    [No Abstract]   [Full Text] [Related]  

  • 32. Intranasal Naloxone for Opioid Overdose.
    Taylor JL; Lasser KE
    JAMA; 2024 Jan; 331(3):250-251. PubMed ID: 38127361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transfer from high dose methadone to buprenorphine/naloxone.
    Wallace M
    Aust Nurs J; 2011 Jul; 19(1):42-3. PubMed ID: 21853690
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study.
    Purssell R; Godwin J; Moe J; Buxton J; Crabtree A; Kestler A; DeWitt C; Scheuermeyer F; Erdelyi S; Balshaw R; Rowe A; Cochrane CK; Ng B; Jiang A; Risi A; Ho V; Brubacher JR
    Clin Toxicol (Phila); 2021 Jan; 59(1):38-46. PubMed ID: 32401548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Commercial factors override science in combination addiction drug trial.
    Byrne A
    Clin Pharmacol Ther; 2011 Nov; 90(5):649; author reply 650. PubMed ID: 21956617
    [No Abstract]   [Full Text] [Related]  

  • 36. Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.
    Dunn KE; Barrett FS; Bigelow GE
    Addict Behav; 2018 Nov; 86():56-60. PubMed ID: 29625751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential.
    Fox L; Nelson LS
    CNS Drugs; 2019 Dec; 33(12):1147-1154. PubMed ID: 31552608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fentanyl misuse.
    Ruzycki S; Yarema M
    CMAJ; 2016 Jun; 188(9):673. PubMed ID: 27091798
    [No Abstract]   [Full Text] [Related]  

  • 40. Buprenorphine implants in medical treatment of opioid addiction.
    Chavoustie S; Frost M; Snyder O; Owen J; Darwish M; Dammerman R; Sanjurjo V
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):799-807. PubMed ID: 28571505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.